Drugs / dirucotide
dirucotide
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT00870155 | Feb 2007 → Sep 2009 | secondary progressive multiple sclerosis | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 2/3 | NCT00869986 | Nov 2006 → Sep 2009 | relapsing-remitting multiple sclerosis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2/3 | NCT00869726 | Dec 2004 → May 2009 | secondary progressive multiple sclerosis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT00468611 | Jun 2007 → Jul 2009 | secondary progressive multiple sclerosis | BioMS Technology Corp. | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2009-07-27 | Eli Lilly and Company | Results Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis lilly.com ↗
In addition, there were no statistically significant differences between dirucotide and placebo on the secondary endpoints of the study. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2009-07-27 | Eli Lilly and Company | Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis lilly.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dirucotide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00869726 ↗ |
| Known as | Dirucotida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105639 ↗ |
| Known as | DIRUCOTIDE ACETATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105639 ↗ |
| Known as | MBP8298 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00468611 ↗ |
| Known as | MBP8298 PEPTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105639 ↗ |
| Known as | SF-328 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105639 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2105639 ↗ |
| Route | Intravenous | “500mg MBP8298 IV every six months for a period of two years” NCT00468611 ↗ |